Scientists hunt for biomarkers to predict immunotherapy success in liver cancer
NCT ID NCT07186010
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is collecting blood and tumor samples from 50 people with advanced liver cancer who are receiving immunotherapy. Researchers will analyze the samples to find genetic and immune system markers that might predict how well the treatment works. The goal is to better understand why some patients respond to immunotherapy and others do not.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which liver cancer patients will benefit most from immunotherapy, leading to more personalized treatment.
- What could go wrong
- This is an early-stage observational study with only 50 participants, so results may not apply to all patients. It is designed to gather information, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
RECRUITINGSeoul, Song-pa, 05505, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?